You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


An Algorithmic Approach to Immunotherapy-Based Treatment in Hepatobiliary Carcinomas 

  • Authors: Amit Singal, MD, MS; Rachna Shroff, MD, MS; Mark Yarchoan, MD 
  • CME / ABIM MOC Released: 11/28/2022
  • Valid for credit through: 11/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, oncologists, primary care physicians, and other clinicians involved in the care of patients at risk of or diagnosed with hepatobiliary cancers.

The goal of this activity is for learners to be better able to increase their knowledge and confidence regarding managing patients with hepatobiliary carcinoma with immunotherapy-based treatments.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Epidemiological patterns of hepatobiliary carcinomas
    • Identification and management of patients who are at risk of developing hepatobiliary carcinoma
    • Immunotherapy-based treatment approaches for patients with hepatobiliary carcinomas in the frontline setting 
    • Role of the multispecialty team in the management of patients with hepatobiliary carcinomas 
  • Demonstrate greater confidence in their ability to
    • Effectively communicate among specialties regarding the care of patients with hepatobiliary carcinoma


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Amit Singal, MD, MS

    Willis C. Maddrey Distinguished Chair in Liver Disease
    Professor of Medicine and Chief of Hepatology
    Medical Director, Liver Tumor Program
    UT Southwestern Medical Center
    Dallas, Texas


    Amit Singal, MD, MS, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; Eisai, Inc.; Exact Sciences Corporation; Exelixis, Inc.; FujiFilm Medical Sciences; Genentech; Glycotest; GRAIL; Roche
    Research funding from: Exact Sciences Corporation; Gilead; Glycotest

  • Rachna Shroff, MD, MS

    Associate Professor of Medicine
    University of Arizona Cancer Center (UACC)
    University of Arizona College of Medicine – Tucson (UA-COM)
    Interim Chief, Division of Hematology/Oncology
    Chief, Section of GI Medical Oncology
    Associate Director of Clinical Investigations, UACC
    Associate Dean, Clinical and Translational Research, UA-COM
    Tucson, Arizona


    Rachna Shroff, MD, MS, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals; Boehringer Ingelheim; CAMI; Clovis; Genentech; Incyte; Merck; QED Therapeutics; Servier, Inc.; Taiho; Zymeworks Biopharmaceuticals
    Speaker or member of speakers bureau for: Servier
    Research funding from: Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology; Novocure; NuCana; Pieris; QED Therapeutics; Rafael Pharmaceuticals; Seagen, Inc.; Taiho

  • Mark Yarchoan, MD

    Associate Professor
    Division of GI Malignancies
    Medical Oncology Director
    Liver Cancer Multidisciplinary Clinic
    Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland


    Participation by Dr Yarchoan does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Mark Yarchoan, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals; Eisai, Inc.; Exelixis, Inc.; Geneos; Genentech; Hepion; Replimune
    Research funding from: Bristol Myers Squibb; Incyte


  • John Churchwell, PhD

    Medical Education Director, Medscape, LLC 


    John Churchwell, PhD, has the following relevant financial relationships:
    Employed by an ineligible company: Medtronic (former)

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


An Algorithmic Approach to Immunotherapy-Based Treatment in Hepatobiliary Carcinomas 

Authors: Amit Singal, MD, MS; Rachna Shroff, MD, MS; Mark Yarchoan, MD Faculty and Disclosures

CME / ABIM MOC Released: 11/28/2022

Valid for credit through: 11/28/2023


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print